A surprisingly strong GDP report boosted investors' spirits. Plus: American depositary receipts for Novo Nordisk rise after U.S. regulators approved a pill version of weight-loss drug Wegovy. Danny Lewis hosts. Sign up for the WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor.